Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples